Acumen Pharmaceuticals, Inc.

NASDAQ:ABOS

Biotechnology

Healthcare
$2.29 +0.67%

+$0.02 today

Market cap
$165.63M
Beta
0.35
P/E (TTM)
-1.3
EPS (TTM)
-$1.79
52W Low $1.10High $3.60

Volume 0.81M

Average 0.40M

ABOS Total Debt

Short-term and long-term borrowings combined.

Acumen Pharmaceuticals, Inc.NASDAQ: ABOS

Total Debt · Q1 FY2026 · quarter ended Mar 2026

Total debt rises 7.5% from a year ago

Total debt stood at $31.16M at the end of Q1 FY2026, up 7.5% from a year earlier and down 0.5% from the prior quarter. Over 3 fiscal years it compounded at +568.1% a year.

Context

  • Total debt amounted to 23.3% of total assets at the end of Q1 FY2026, up 9.1 pp from a year earlier.
  • Total debt increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether total debt keeps rising in the next quarterly balance sheet after a +7.5% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$31.16M-0.5% QoQ
Last fiscal yearDec 2025
$31.31M+5.4% YoY
Year agoMar 2025
$29M+7.5% since
Total Debt past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+7.5%——
1 year+5.4%——
3-year CAGR+568.1%——
5-year CAGR——
10-year CAGR——

Total Debt history

USD · from the balance sheet

Latest · FY2025
31.31M USD
Year-over-year change
+5.4%

Total Debt vs competitors

How ABOS compares with its peers on the latest reported figures

  • ABOS's Mar 2026 total debt of $31.16M is the 5th highest of the 10 companies compared; the peer median is $25.93M.
  • Its year-over-year change of +7.5% is the 2nd highest of 8, against a peer median of -10.1%.
  • Total debt amounts to 23.3% of total assets for ABOS, versus a peer median of 17.5%.
ABOS Competitors Peer median
Total Debt for ABOS and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
AGENAgenus Inc.Mar 2026$304.46M +230.8%+62.2%163.3%
MCRBSeres Therapeutics, Inc.Mar 2026$80.5M -10.1%-20.1%68.4%
FATEFate Therapeutics, Inc.Mar 2026$76.79M -7.9%-10.7%27.0%
ALECAlector, Inc.Mar 2026$34.55M -15.8%-5.8%14.4%
ABOSAcumen Pharmaceuticals, Inc.Mar 2026$31.16M +7.5%+568.1%23.3%
IRDOpus Genetics, Inc.Mar 2026$25.93M ——38.8%
SEERSeer, Inc.Mar 2026$23.03M -9.4%-7.5%8.5%
INOInovio Pharmaceuticals, Inc.Mar 2026$8.7M -22.9%-33.7%17.5%
SPROSpero Therapeutics, Inc.Mar 2026$2.47M -37.5%-24.2%4.2%
ACTUActuate Therapeutics IncMar 2026$404.99K —+0.0%4.5%
Peer median (excluding ABOS) $25.93M-10.1%-9.1%17.5%

Competitors are the stored peer set for ABOS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents122.16M130.1M66.89M35.63M53.99M
Short-term Investments72.08M47.5M176.64M135.93M62.88M
Net Receivables00225K0625K
Inventory0199K0159K0
Other Current Assets2.83M1.42M1.96M5.73M4.16M
Total Current Assets198.66M180.33M246.62M178.31M122.25M
Property, Plant & Equipment (Net)36K270K503K339K243K
Goodwill00000
Intangible Assets00169K029K
Long-term Investments31.62M15.84M62.55M59.97M0
Tax Assets0000163K
Other Non-current Assets14K151K285K379K146K
Total Non-current Assets31.67M16.26M63.51M60.69M581K
Total Assets230.33M196.59M310.13M238.99M122.83M
Account Payables1.09M1.64M1.38M5.65M554K
Short-term Debt00008.92M
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities2.96M131K3.9M230K4.25M
Total Current Liabilities5.15M7.81M12.97M27.61M30.01M
Long-term Debt0027.34M29.42M22.4M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities002.56M00
Total Non-current Liabilities0030.18M29.57M22.4M
Total Liabilities5.15M7.81M43.15M57.18M52.4M
Common Stock4K4K6K6K6K
Retained Earnings(127.57M)(170.43M)(222.8M)(325.13M)(446.46M)
Accumulated OCI(231K)(751K)312K(48K)83K
Other Stockholders Equity00000
Minority Interest00000
Total Equity225.18M188.78M266.97M181.82M70.43M
Total Debt0105K28.49M29.7M31.31M
Net Debt(122.16M)(130M)(38.4M)(5.93M)(22.68M)

Acumen Pharmaceuticals, Inc.

NASDAQ:ABOS

Intrinsic Alpha fair value

Locked

Current Price

$2.29

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.